Tokyo, Jan. 25 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060451) titled 'A Longitudinal Observational Study Investigating the Association Between Amyloid Pathology and Electroencephalographic Findings' on Jan. 23.
Study Type:
Observational
Primary Sponsor:
Institute - the University of Osaka
Condition:
Condition - Patients who are considered, based on the treating physician's clinical judgment, to be potentially eligible for anti-amyloid beta antibody therapy
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To elucidate the association between amyloid pathology and electroencephalographic characteristics.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 40
years-old
=
Gender - Male and Female
Key inclusion criteria - Patients who are considered, based on the treating physician's clinical judgment, to be potentially eligible for anti-amyloid beta antibody therapy
Key exclusion criteria - Patients who are judged by the treating physician to be inappropriate for participation in this study, based on the patient's clinical condition and the purpose of the study.
Target Size - 300
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 01 Month 23 Day
Anticipated trial start date - 2026 Year 02 Month 01 Day
Last follow-up date - 2030 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069167
Disclaimer: Curated by HT Syndication.
